MBI gears up for Phase II trials of FSO69:
This article was originally published in Clinica
Molecular Biosystems (US) plans to begin Phase II trials of its organ perfusion ultrasound contrast agent, FSO69, in the autumn following the successful completion of Phase I trials. Left ventricular border enhancement and myocardial perfusion were observed in all subjects in the initial trial, says MBI. Safety of the second generation agent has been demonstrated, says chairman and CEO Kenneth Widder. "Future clinical studies will be performed to verify efficacy in the liver and kidneys."
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.